Omeros Q2 FY26 net income drops to $13.2 million; revenue more than doubles to $28.5 million quarter-over-quarter
OMER•Q2 FY26 financial results
- Omeros posted Q2 net sales of USD 28.5 million as YARTEMLEA gross revenue more than doubled to USD 32.2 million.
- Net income fell to USD 13.2 million, or USD 0.18 per share, from USD 56.1 million, or USD 0.78 per share, in Q1.
- Results included an USD 11.5 million non-cash gain tied to the 2029 Notes; non-GAAP adjusted net income was USD 1.8 million.
- Cash and short-term investments totaled USD 132 million at June 30; operating cash flow was USD 4.1 million.
Regulatory update on narsoplimab in Europe
- CHMP adopted a negative opinion on the EU narsoplimab MAA in TA-TMA; re-examination requested, expanded access continues in Europe.
